MH
Michael R Hayden
Director

Michael R Hayden insider trades: AbCellera Biologics (ABCL) stock buys and sales

Director, AbCellera Biologics Last trade Aug 24, 2026 64 Form 4 filings
$0
Sold, last 12 months
0 sales
$1.1M
Bought, last 12 months
2 buys
11
Open-market trades
since 2017
5
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Michael reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 24, 2026ABCL↑ Buy$570K
Aug 12, 2026ABCL↑ Buy$481K
May 1, 2025IONS↑ Buy$478K
Dec 23, 2024IONS↑ Buy$181K
Sep 22, 2023ABCL↑ Buy$98K
Aug 8, 2023ABCL↑ Buy$177K
Mar 28, 2023ETNB↑ Buy$1.1M
Jun 22, 2021ABCL↓ Sell$2.5M
Dec 15, 2020ABCL↑ Buy$1.5M
Nov 11, 2019ETNB↑ Buy$300K
Aug 14, 2017XENE↑ Buy$41K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ABCL insiders

Open-market trades in the last 12 months

About Michael R Hayden's insider trades

Michael R Hayden is a director at AbCellera Biologics (ABCL). Since Aug 14, 2017, Michael has reported 10 open-market purchases worth $4.9M and 1 sale worth $2.5M on SEC Form 4. In the last 12 months: 2 buys ($1.1M).

Their filings also include grants and awards (31 filings), option exercises (20 filings), gifts (3 filings), conversions (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ABCL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.